4CPS-035 Effectiveness and safety of monoclonal antibody pcsk9 inhibitors

BACKGROUND: Monoclonal antibody PCSK9-Inhibitors (PCSK9i), alirocumab and evolocumab, are a new class of drugs used to decrease LDL cholesterol (LDLc) and can be an option for patients with heterozygous familial hypercholesterolaemia (HeFH) and cardiovascular diseases (CVD) with high levels of LDLc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Martin, V Merino, Ortega-Garcia, MP, Blasco-Segura, P, Garcia, J Sanfeliu, Carrasco, A Lopez, Cristobal, R del Rio San, Guasp, I Toledo
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 4: Clinical pharmacy services
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535419/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.126
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars